Choroidal naevus regression associated with PD-1 inhibitor monotherapy for metastatic cutaneous malignant melanoma

被引：2
|
作者：
Krohn, Jorgen [1 ,2 ]
Hanken, Geir [3 ]
Herlofsen, Oluf [4 ]
机构：
[1] Univ Bergen, Dept Clin Med, Sect Ophthalmol, Bergen, Norway
[2] Haukeland Hosp, Dept Ophthalmol, N-5021 Bergen, Norway
[3] More & Romsdal Hosp Trust, Alesund Hosp, Dept Ophthalmol, Alesund, Norway
[4] More & Romsdal Hosp Trust, Alesund Hosp, Dept Oncol, Alesund, Norway
来源：
ACTA OPHTHALMOLOGICA | 2020年 / 98卷 / 02期
关键词：
D O I：
10.1111/aos.14237
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：E262 / E264
页数：3
相关论文
共 50 条
  • [21] Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma
    Vanella, Vito
    Festino, Lucia
    Vitale, Maria Grazia
    Alfano, Benedetta
    Ascierto, Paolo Antonio
    EXPERT OPINION ON EMERGING DRUGS, 2021, 26 (02) : 79 - 92
  • [22] A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
    Girault, Isabelle
    Adam, Julien
    Shen, Shensi
    Roy, Severine
    Brard, Caroline
    Faouzi, Sara
    Routier, Emilie
    Lupu, Jeremy
    Warren, Sarah
    Sorg, Kristina
    Ong, SuFey
    Morel, Pascale
    Scoazec, Jean-Yves
    Vagner, Stephan
    Robert, Caroline
    CLINICAL CANCER RESEARCH, 2022, 28 (03) : 518 - 525
  • [23] Complete Remission of a metastatic malignant Melanoma by the PD-1 Antibody Pembrolizumab after BRAF Inhibition and Ipilimumab
    Alhumam, A.
    Haalck, T.
    Ruhde, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 169 - 170
  • [24] PD-1 Antibodies A new Treatment Option for metastatic Melanoma
    Hafner, C.
    HAUTARZT, 2012, 63 (09): : 724 - 725
  • [25] PD-1 inhibition in congenital pigment synthesizing metastatic melanoma
    Weyand, Angela C.
    Mody, Rajen J.
    Rabah, Raja M.
    Opipari, Valerie P.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (01)
  • [26] Pulmonary and Cutaneous Sarcoidosis Secondary to the Use of PD-1 Inhibitor
    Kapil, R.
    Guadarrama, D.
    Mangala, Y. Onkarappa
    El-Bizri, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [27] PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis
    Chen, Long
    Mo, Dun-Chang
    Hu, Min
    Zhao, Shi-Jie
    Yang, Qiang-Wei
    Huang, Zhi-Ling
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2022, 43 (02)
  • [28] Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
    Tjulandin, Sergey
    Demidov, Lev
    Moiseyenko, Vladimir
    Protsenko, Svetlana
    Semiglazova, Tatiana
    Odintsova, Svetlana
    Zukov, Ruslan
    Lazarev, Sergey
    Makarova, Yuliya
    Nechaeva, Marina
    Sakaeva, Dina
    Andreev, Aleksey
    Tarasova, Anna
    Fadeyeva, Natalya
    Shustova, Mariia
    Kuryshev, Ivan
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 222 - 232
  • [29] Tolerance and Efficacy of Combined Nivolumab and Ipilimumab Following Monotherapy with PD-1 or CTLA-4 Blockade in Metastatic Melanoma
    Randhawa, M.
    Nguyen, B.
    Ali, S.
    Yip, D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 71 - 71
  • [30] Immunotherapy associated cutaneous reaction in patients presenting with metastatic malignant melanoma
    Karai, L.
    Karne, N.
    Lee, C.
    Stern, J.
    Turner, M.
    Rosenberg, S.
    Bergfeld, W.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2008, 35 (01) : 132 - 132
12345